Immune targets and neoantigens for cancer immunotherapy and precision medicine

@article{Wang2017ImmuneTA,
  title={Immune targets and neoantigens for cancer immunotherapy and precision medicine},
  author={Rong-fu Wang and Helen Y Wang},
  journal={Cell Research},
  year={2017},
  volume={27},
  pages={11-37}
}
Harnessing the immune system to eradicate malignant cells is becoming a most powerful new approach to cancer therapy. FDA approval of the immunotherapy-based drugs, sipuleucel-T (Provenge), ipilimumab (Yervoy, anti-CTLA-4), and more recently, the programmed cell death (PD)-1 antibody (pembrolizumab, Keytruda), for the treatment of multiple types of cancer has greatly advanced research and clinical studies in the field of cancer immunotherapy. Furthermore, recent clinical trials, using NY-ESO-1… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS
24 Extracted Citations
224 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 24 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 224 references

Similar Papers

Loading similar papers…